Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.45 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254651 | 0.87 | MAPT (0.61) | MAPTHPGDCYP3A4NOS1LMNA | |
| SCHEMBL30235066 | 0.87 | MAPT (0.61) | MAPTHPGDCYP3A4NOS1LMNA | |
| SCHEMBL2931498 | 0.81 | JAK2 (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL29431208 | 0.81 | JAK2 (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL30833662 | 0.81 | DAO (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL921416 | 0.81 | DAO (0.51) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL11145798 | 0.81 | MAPT (0.58) | MAPTHPGDDAONOS1LMNA | |
| SCHEMBL4262245 | 0.81 | PARP1 (0.49) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL4057244 | 0.81 | PARP1 (0.53) | MAPTHPGDDAOCYP3A4NOS1 | |
| SCHEMBL2926701 | 0.80 | MAPT (0.50) | MAPTHPGDDAOCYP3A4NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| CN-110546150-B | Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-109761986-B | Tricyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20210238173-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 INHIBITORS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-08-05 | — | — | US | disclosed |
| CN-112236414-A | Mitogen-activated protein kinase 7 inhibitors | 耶达研究及发展有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2020251974-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3699179-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| CN-1300116-C | 1H-indazole compounds | EISAI CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-7071182-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-07-04 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| CN-1512987-A | Novel 1H-indazole compound | ������������ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238173-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 INHIBITORS | MAPK7, MAP2K7, MAP3K7 | MAPT 1774/4885HPGD 1266/4885DAO 1218/4885 |
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MAPT 228/4885HPGD 2707/4885DAO 415/4885 |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MAPT 228/4885HPGD 2707/4885DAO 415/4885 |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | MAPK1, MAPK11, MAPK14 | MAPT 3727/4885HPGD 191/4885DAO 2790/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | MAPT 2892/4885HPGD 1866/4885DAO 915/4885 |
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCA1, SMARCE1, PBRM1 | MAPT 1576/4885HPGD 3740/4885DAO 3790/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | MAPT 623/4885HPGD 3637/4885DAO 2262/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPT 2644/4885HPGD 1817/4885DAO 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.